Bellicum Pharmaceuticals, Inc. is focused on the development of next generation therapeutic vaccines and other immunotherapeutic approaches for the treatment of cancer. Founded in July 2004 by Professors Kevin M. Slawin, M.D. and David M. Spencer, Ph.D., the company is developing clinical products based on novel and powerful vaccine strategies developed at Baylor College of Medicine. The company's lead product, BP-GMAX-CD1, a genetically modified, pharmacologically regulated autologous vaccine, is in late stage preclinical development for patients with advanced, androgen independent prostate cancer.

The company’s new technology will provide a novel way of relieving peripheral nerve pain by using a small wireless neurostimulation device implanted into a patient rather than relying on drug treatments to relieve a patient’s pain.

MicroTransponder focuses on creating entirely new ways to treat nerve pain caused by diabetic neuropathy. Currently, the company is collaborating with the University of Texas at Dallas to license and patent their emerging technology and expects to collaborate with MD Anderson once preliminary testing begins.

 (Acquired by Volcano Corp, Dec. 2007)

CardioSpectra is a privately-held company developing innovative Optical Coherence Tomography (OCT) technology. CardioSpectra's unique OCT imaging system is expected to complement Volcano's existing product offerings and will further enhance Volcano's position as an imaging technology leader in the field of interventional medicine.

Nanospectra Biosciences is developing a nanoparticle-based cancer therapy that is broadly applicable to solid tumors. The Company has an approved IDE with FDA and will commence its first clinical trial in head and neck cancer during 2008. This therapy utilizes the nanophotonic properties of a new class of nanoparticles which are delivered intravenously to the tumor and then activated by a near-infrared laser, resulting in the precise thermal destruction of the tumor and the blood vessels supplying them without significant damage to healthy tissue.

PLx Pharma is a Houston, Texas based pharmaceutical company developing GI safer NSAIDs (nonsteroidal anti-inflammatory drugs, such as ibuprofen, naproxen and aspirin) utilizing its novel proprietary phospholipid based technology. This technology complexes a natural soy derived Phosphatidylcholine (PC) with a traditional NSAID to mitigate NSAIDs GI toxicity. PLx’s lead products are GI safer oral complexes with Phosphatidylcholine of ibuprofen (PL 1100 Ibuprofen-PC), naproxen (PL 3100 Naproxen-PC) and aspirin (PL 2100 Aspirin-PC). Additional dose forms including IV delivery of Indomethacin-PC and other NSAID-PC products along with other drug combinations complexed with PC are also in development.

Diabetica Solutions Inc. has focused on the development of medical device products for people suffering with diabetes and susceptible to foot-related problems. Our signature product is the TempTouch, a non-invasive device that a person with diabetes uses at home on a daily basis to detect temperature changes that can lead to foot ulcers and amputations. Future pipeline products will enhance remote access to data and expand the interaction between patient and physician.

Quantum Logic Devices is a Georgetown TX nanotechnology company founded in 2000 to commercialize molecular-scale transistors for biological testing and electronics. The company’s core technology encompasses single-electron devices that enable a simpler way to analyze DNA, protein, and molecular interactions without optical labels and complex testing procedures. The binding reaction itself causes unambiguous changes in conductivity that provide quantitative measure of target analytes down to single molecules. QLD is engaging partners that bring bioassays for specific applications to create market-leading products for research and medical diagnostics.

Endothelix is positioned as the first company to incorporate non-invasive, non-imaging vascular function monitoring technologies to improve existing risk factor assessment to help physicians more accurately monitor their patients’ cardiovascular health, and to use appropriate therapies for the prevention and treatment of heart attack and stroke.

Receptor Logic, Inc. is a life science company providing powerful tools for medical research, diagnostics, and treatment of diseases such as cancer. Our knowledge of the underlying science of the immune system has led to the groundbreaking discovery and development of T Cell Receptor mimic (TCRm) technology – a specialized monoclonal antibody for use in disease research, vaccine development, and treatment of cancer. 

Halsa Pharmaceuticals, Inc. is a start-up biotechnology company developing therapeutics for the treatment of obesity and other metabolic diseases. Halsa Pharmaceuticals has achieved exclusive patent rights to a natural material that, when injected by a physician into an obese patient, will cause immediate and substantial depletion of body fat. Respected organizations provide significant evidence that validates the technology.

Resonant Sensors Incorporated has an approach for biological and molecular monitoring that doesn’t require the use of chemical labels or post processing steps. This optical sensor technology enables rapid, high-precision analysis of biochemical reactions in real-time. Our innovative sensor systems dramatically reduce the processing time of biomolecular assays. 

   Laser Tissue Welding 

Laser Tissue Welding, Inc is a biotechnology company providing life saving human therapeutics based on advances in Laser assisted tissue welding technology. It was founded in 2004 as a Delaware C Corp with manufacturing facilities located in Humble, Texas. LTW is vertically integrated with in-house innovation, design, research, and development, manufacturing and marketing. Sales are through specialty distributors.

Seno Medical Instruments is a cancer focused company. Seno’s patented technology is opto-acoustics which uses dual-wavelength lasers to pulse light into tissue to discover a lesion. If a lesion is present, it will absorb the light energy and create a 3-D sound wave. This sound wave yields an image in real-time which makes the tumor “speak to us.”

Seno’s imaging modality uniquely informs the user (physician/researcher) if a lesion is cancerous by revealing the two basic causes of cancer: the growth of blood vessels, angiogenesis, and the absence of oxygen. Never before has the hemoglobin map of a living animal or human been available for research or diagnostic purposes. Seno targets all solid cancerous tumors addressing multi-billion dollar markets. 

We are in the business of creating new drug leads. Utilizing our proprietary protein "re-engineering" capabilities, Molecular LogiX can evaluate specific modifications of clinically-relevant proteins to create new therapeutic properties. Our efforts are focused on the development of new "Dominant Negative Ligands" for the treatment of important diseases. Our primary work is devoted to the development of a new "Pan-HER Anti-Cancer Ligand" to treat tumors that have become resistant to current molecular targeting therapies.

Terapio is developing a pipeline of systemic and topical therapies based on the normally-occurring transport protein RLIP76. The RLIP76 protein moves free-radical toxins out of cells before significant damage can occur. While naturally present in cells, increasing the amount of this protein available to normal cells affords them an even greater ability to deal with toxins from a variety of sources, including chemicals and radiation.

Monebo Technologies, Inc. is a medical technology company dedicated to providing technology solutions that monitor, assess, and interpret the electrical activity of the heart. The company has two platform technologies, the ECGAnalyzer™ software suite for automatic electrocardiogram (ECG) interpretation, and the CardioBelt™ ECG acquisition device for remote ECG monitoring. Monebo has received regulatory clearance from the United States Food and Drug Administration (FDA) to market ECGAnalyzer™ and has contracts with the world’s leading cardiac monitoring service companies. The CardioBelt has received 510(k) clearance and Monebo has obtained contracts with several major providers to the Home Health Care market and the cardiac monitoring space. Several trials are beginning. Profound positive changes are underway in the Prospective Payment System (PPS) administered by the Center for Medicare and Medicaid Services (CMS) which will dramatically affect the market acceptance of Monebo’s products in the home healthcare space.

ThromboVision, Inc. is a biomedical company committed to enabling people to lead longer and healthier lives. ThromboVision provides easy-to-use, rapid-response, cost-effective, and versatile point-of-care clinical diagnostic discoveries that advance medical diagnosis. The company’s products will improve medical care by assisting physicians in diagnosing and managing critical cardiovascular risk factors, especially those related to platelet function and antiplatelet drug therapy.

OrthoAccel Technologies, Inc. is developing a daily-use dental device to shorten orthodontic treatment time through the use of pulsating forces to enhance the constant pressure of the braces. Less time in braces not only fulfills an important esthetic patient demand, it is also associated with safer case finishing and allows the orthodontist to operate more efficiently through a reduction in the required number of patient visits. The company currently has its first generation device in clinical trials at the UT Houston Dental Branch. The commercial launch is being planned for late 2009. 

Visualase, Inc. develops, manufactures, and sells a minimally invasive thermal therapy and monitoring system and disposables that will enable destruction of solid cancerous tumors. The patented Visualase® Thermal Therapy System employs magnetic resonance imaging (MRI) analysis software, an advanced medical laser, and unique applicator system to thermally “cook” tumors and provide real-time feedback and control of the treatment process. The surgeon can thus target and destroy only the tumor, leaving the surrounding tissue unharmed. Our first applications are the minimally invasive treatment of primary and metastatic tumors in the brain and spinal bodies.